49
Participants
Start Date
May 31, 2001
Primary Completion Date
May 31, 2003
Study Completion Date
May 31, 2003
Herceptin
Intravenously every week for 12 weeks (weeks 1-12) Intravenously every three weeks for 40 weeks (weeks 32-72)
Navelbine
Intravenously every week for 12 weeks
Doxorubicin
Every 3 weeks for 12 weeks
Cyclophosphamide
Intravenously every 3 weeks for 12 weeks
Paclitaxel
Weekly for 12 weeks (or a similar schedule)
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Center, Boston
Massachusetts General Hospital
OTHER
Beth Israel Deaconess Medical Center
OTHER
Brigham and Women's Hospital
OTHER
Dana-Farber Cancer Institute
OTHER